Fig. 5
From: Imaging modalities in differential diagnosis of Parkinson’s disease: opportunities and challenges

The administration of iodine-123 metaiodobenzylguanidine (123I-MIBG) and its uptake in Parkinson’s disease (PD) (left) and multiple system atrophy (MSA) (right). Normal heart uptake in the MSA patient is seen. The image shows extensive liver uptake in both patients [104]